Idvynso (doravirine and islatravir)
Merck Sharp & Dohme (MRK)
ApprovedApr 20, 2026
Marketer take
A two-drug switch regimen for virologically suppressed adults, competing with Dovato, Biktarvy and long-acting injectables in regimen-simplification conversations with HIV specialists.
- Sponsor company
- Merck Sharp & Dohme (MRK)
- Indication
- To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine
- Therapeutic area
- Infectious disease
- Event
- FDA approval
- Date
- Apr 20, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?